OncoQuest has entered into a collaborative agreement with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab (MAb B43.13) with Zejula (niraparib) in recurrent ovarian cancer. Oregovomab is ... Read more